There was no verified, sweeping Trump Medicare overhaul in August 2026. The main late-August CMS announcement concerned laboratory fraud enforcement, not broad changes to Medicare eligibility or benefits. Other Medicare developments do matter for 2026 and 2027. They include a temporary GLP-1 access program, negotiated drug prices, the end of a Part D premium demonstration, and upcoming plan details.
Official resources:
- Check eligibility on CMS’s official study page — Use this page to check the study’s participation requirements.
- Register through CMS’s official page — Use this page to review requirements and register directly.
Table of Contents
- What actually changed in August?
- Why 2027 Part D premiums remain uncertain
- Which prescription drug changes affect patients?
- What the Medicare Advantage payment increase means
- What beneficiaries should watch next
What actually changed in August?
On august 28, the Centers for Medicare & Medicaid Services, or CMS, announced actions targeting potentially improper laboratory payments. CMS said it had stopped more than $1.6 billion in such payments, including $732 million tied to revoking 157 laboratory providers, according to the agency's Medicare fraud enforcement release. That announcement did not establish new eligibility rules, cut Medicare benefits, or set new premiums for all beneficiaries.
It described program-integrity enforcement intended to prevent public funds from reaching providers CMS considered fraudulent. Beneficiaries may still feel indirect effects if a laboratory loses Medicare billing privileges. Anyone receiving a notice about a lab claim should compare it with services actually received and contact Medicare if the provider, test, or date is unfamiliar.
Why 2027 Part D premiums remain uncertain
CMS will end the voluntary Part D Premium Stabilization Demonstration after 2026. The demonstration temporarily altered how participating standalone prescription drug plans handled premium changes; those plans return to traditional market conditions in 2027. CMS set the 2027 Part D national base beneficiary premium at $41.33.
That figure is an input used in the federal premium formula—not the amount every enrollee will pay. The Inflation Reduction Act limits the base premium's annual increase to 6% through 2029, as CMS explains in its 2027 Part D premium information. Actual premiums can differ by plan. Formularies, pharmacy networks, deductibles, and drug cost-sharing can also change, so the lowest premium may not produce the lowest total annual cost.
Which prescription drug changes affect patients?
The first negotiated Medicare prices for 10 Part D drugs took effect january 1, 2026. CMS estimates those drugs served about 8.8 million Part D enrollees in 2023 and could save beneficiaries about $1.5 billion under the standard benefit. CMS also finalized 2027 rules preserving the redesigned Part D benefit.
Those rules codify the end of the coverage gap, maintain an annual out-of-pocket threshold, and require zero cost-sharing in the catastrophic phase. A separate temporary program, the GLP-1 Bridge, runs from July 1, 2026, through December 31, 2027, for eligible Part D beneficiaries. CMS sets a $50 copay, but the drugs sit outside Part D. Consequently, the payment does not count toward the Part D deductible or out-of-pocket threshold, and no low-income subsidy applies, according to the agency's GLP-1 Bridge guidance.
What the Medicare Advantage payment increase means
CMS projects that average payments to Medicare Advantage plans will rise 2.48% in 2027, an increase exceeding $13 billion. Medicare Advantage plans are private health plans that contract with Medicare to provide covered benefits. That projection concerns payments to insurers.
It does not prove that an individual enrollee's premium will fall, benefits will expand, or cost-sharing will improve. Plans still determine many consumer-facing details within Medicare rules. A beneficiary therefore needs the plan's final premium, provider network, drug list, benefit limits, and cost-sharing—not the national payment percentage—to judge whether coverage improved.
What beneficiaries should watch next
CMS expects to release final 2027 Medicare Advantage and Part D offerings and average premiums in mid-to-late September. Until then, claims about a person's exact 2027 plan premium or benefits are premature. When final plan information becomes available: A plan with a slightly higher premium may cost less overall if it covers essential drugs more favorably or keeps preferred providers in network.
- Confirm that doctors, hospitals, pharmacies, and prescriptions remain covered.
- Compare total expected costs, not just the monthly premium.
- Check whether medications require prior authorization or have changed tiers.
- Treat the $41.33 base premium as a formula figure, not a personal quote.
- Review every Medicare Summary Notice for laboratory services you did not receive.